Plasma pTau217 as a Prognostic, Monitoring, and Risk-Stratification Biomarker of Clinical Progression in Lewy Body Disease

medRxiv (preprint – not peer reviewed) |

S A Lorkiewicz, C Abdelnour, M Bolen, A M Smith, M Shahid-Besanti, D Hemachandra, E M Müller-Oehring, N Siddiqui, L Montoliu-Gaya, B Arslan, N J Ashton, E N Wilson, L Tian, K I Andreasson, E C Mormino, V W Henderson, H Zetterberg, K L Poston

BACKGROUND AND OBJECTIVES: In Lewy body disease (LBD), co-occurring Alzheimer's disease (AD) neuropathologic change (ADNC) is associated with worse clinical outcomes. While plasma pTau217 detects ADNC in LBD, its prognostic, monitoring, and risk-stratification utility remains unclear. We evaluated whether plasma pTau217 predicted cognitive and functional decline and risk for progression to MCI or dementia in LBD.